Why the study?
Do agents affecting platelet function (dipyridamole, aspirin, dextran) prevent venous thrombosis and pulmonary embolism compared to warfarin in patients undergoing vitallium-mold arthroplasty of the hip?
Do agents affecting platelet function (dipyridamole, aspirin, dextran) prevent venous thrombosis and pulmonary embolism compared to warfarin in patients undergoing vitallium-mold arthroplasty of the hip?
Answers are grounded in this paper and cite their sources.
Aspirin and dextran appear to offer similar protection against thromboembolic complications as warfarin in patients undergoing hip arthroplasty, whereas dipyridamole is less effective.
The protection against venous thrombosis and pulmonary embolism afforded by three drugs affecting platelet function was assessed in a controlled study of 169 patients undergoing vitallium-mold arthroplasty of the hip. The prophylactic administration of dipyridamole, aspirin and dextran was compared with the effects of warfarin. Thromboembolic complications occurred in six of 43 patients who received warfarin, nine of 34 receiving dipyridamole, six of 43 receiving aspirin and six of 49 receiving dextran. These results with aspirin, dextran and warfarin, but not dipyridamole, are better than those in an untreated group previously reported (26 thromboembolic complications in 67 patients). The frequency of bleeding complications did not differ in the four groups.
No takes yet. Share an insight, caveat, or question.
Salzman et al. (1971) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: